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Abbreviations used
ABMR: Antibody-mediated rejection
DSA: Donor-specific antibody
HRP: Horseradish peroxidase
MFI: Median fluorescence intensity
PE: Phycoerythrin
RBL: Rat basophil leukemia
SAB: Single-antigen bead
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2 FARKAS ET ALmurine strain combinations, as well as during chronic antibody-
mediated heart graft rejection. Anti-HLA IgE, including donor
HLA class I and II specificities, was identified in a group of
sensitized transplant recipients. Murine and human
anti-MHC/HLA IgE triggered mediator release in coated
basophils on stimulation with specific MHC/HLA antigens.
HLA-specific IgE was not linked to atopy, and allergen-specific
IgE present in allergic patients did not cross-react with HLA
antigens. FcεRI1 cells were found in the human renal cortex
and medulla and provide targets for HLA-specific IgE.
Conclusion: These results demonstrate that MHC/HLA-specific
IgE develops during an alloresponse and is functional in
mediating effector mechanisms. (J Allergy Clin Immunol
2018;nnn:nnn-nnn.)
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Despite considerable improvements in 1-year graft survival
over the last decades, long-term kidney graft survival has largely
stagnated and remains suboptimal.1,2 Immunologic graft injury is
still the leading cause of late graft loss, and antibody-mediated
rejection (ABMR) is widely considered the most important
predictor andmediator of late graft injury.3,4 Consequently, recent
research has focused on investigating the occurrence of
donor-specific antibodies (DSAs) and in particular anti-HLA
DSAs and their pathophysiologic role in renal graft damage.5
Increasingly, DSAs are recognized as important in liver, heart,
and lung transplantation as well.6-9
Among HLA DSAs, both preformed (ie, present at baseline
before transplantation)10,11 and de novo (ie, newly developing
after transplantation)11-14 antibodies are recognized to affect graft
survival. Approximately 30% of transplant candidates show
preformed HLA-specific antibodies, and roughly 20% to 30%
have de novo DSAs after transplantation.5
DSAs are predominantly of the IgG isotype (ie, antibody
subtype), with IgM and IgA DSAs also described.15 Recently,
distinct effects for the IgG subclasses IgG1 to IgG4 have been
reported.16,17 However, little is known about the role of other
isotypes, and to the best of our knowledge, anti-HLA IgE has
not been reported to date. Solid-phase assays measuring
antigen-specific antibodies in patient sera have been
developed for diagnostic purposes. In particular, Luminex-
based measurement of antibodies of the IgG isotype against a
high number of individual HLA antigens (approximately 100
for class I and approximately 100 for class II) is used routinely
in many transplantation centers.
Importantly, however, not all DSAs have an immediate
negative effects on outcome because a proportion of
DSA-positive recipients maintain unimpaired graft function for
a considerable period of time. For instance, although
approximately 90% of patients with histologic features of
ABMR in late failing heart allografts had detectable DSAs, a
substantial proportion (approximately 35%) of patients devoid of
histologic ABMR features also had detectable DSAs.18 Thus,
measurement of DSAs in transplant candidates and recipients is
a valuable diagnostic tool but is typically insufficient on its own
to allow individualized clinical decision making. Therefore, it is
important to better understand the biology of the humoral
allograft response and its mechanisms of affecting the graft. Inthis respect, efforts are ongoing to defineDSA subsets with higher
potency of causing graft injury. The complement-binding fraction
of IgG DSAs is a step in this direction,13,19-23 but the clinical
utility of this parameter is still under debate.
IgE is an antibody isotypewith unique nonredundant functional
properties and effector mechanisms that are not shared by other
isotypes.24 In contrast to other isotypes that are most abundant in
serum, IgE is mostly found in tissue and is present in serum in
only very low amounts (approximately 10,000-fold lower than
IgG).24 In tissue IgE binds tightly to mast cells and basophils
through the specific high-affinity receptor FcεRI. Mast cell
degranulation is triggered on cross-linking of IgE through
binding of specific antigen, releasing potent proinflammatory
mediators (including TNF-a and IL-6). IgE plays a prominent
role in TH2-type immune disorders, in particular type I allergy
and parasite infection. However, additional IgE-mediated
mechanisms are also increasingly recognized. Notably,
autoantibodies of the IgE isotypes develop in TH2-driven
immunity in patients with lupus and atopic dermatitis,25-27 and
increased IgE levels seem to play a role in atherosclerosis.28
The cellular immune response to allografts is recognized to
include features of TH2 immunity in some rejection settings.
29-31
However, the occurrence and potential relevance of IgE in
graft-directed immunity in transplantation has not been
investigated thus far.
In the present study we reveal that IgE antibodies specific for
donor MHC class I and MHC class II antigens developed during
graft rejection in several mouse transplantation models. The
induced MHC-specific IgE was functional and mediated effector
cell degranulation in vitro and in vivo on specific antigen
stimulation. Moreover, we identified donor HLA-specific IgE in
sera of sensitized kidney transplant patients, which was also
functional in vitro and demonstrates that FcεRI1 target cells are
present in human kidneys.METHODS
The Methods are available in this article’s Online Repository at
www.jacionline.org.RESULTS
MHC-specific IgE is induced on rejection of
allogeneic skin and heart allografts
BALB/c (H-2d) tail skin was grafted onto naive fully
mismatched C57BL/6 (H-2b) mice and recipient serum was
analyzed for IgE specific for Kd and Dd (ie, MHC class I) and
I-Ed (ie, MHC class II) through an ELISA using recombinant
MHC monomers to investigate whether anti-donor IgE develops
FIG 1. Donor MHC–specific IgE rapidly develops after allogeneic murine skin and heart transplantation.
A-C and G-I, Analysis of IgE specific for MHC class I (ie, H-2Kd and H-2Dd; Fig 1, A and B, skin; Fig 1, G and H,
heart) 3 and 5 weeks (w) after transplantation and MHC class II (ie, I-Ed; Fig 1, C, skin; Fig 1, I, heart) 5 weeks
after transplantation in the setting of BALB/c transplants to C57BL/6 or C3H recipients.D-F and J-L, The same
analysis was done for H-2Kk, H-2Dk (Fig 1, D and E, skin; Fig 1, J and K, heart) and I-Ek (Fig 1, F, skin; Fig 1, L,
heart) in the setting of C3H transplants to C57BL/6 or BALB/C recipients. Serum was pooled for analysis of
I-Ed– and I-Ek–specific IgE to accommodate the high amount of serum required. Results pooled from 2
experiments are shown (n 5 6 for all skin and n 5 4 for all heart transplant experiments). P values were
calculated with the Mann-Whitney U test. *P < .05 and P > .01, **P <_ .01 and P > .001, and ***P <_ .001,
respectively. HTX, Heart transplantation; pre, pre-transplantation; STX, skin transplantation.
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FARKAS ET AL 3during allograft rejection. Additionally, BALB/c tail skin was
grafted onto C3H (H-2k) mice to control for strain-specific
effects. All grafts were rejected within 12 days.
In both recipient strains Kd- and Dd-specific IgE was
consistently detectable in sera of all recipients at 3 and 5 weeks
after transplantation (Fig 1). MHC class I–specific IgE serum
levels remained stable until at least 6 months after
transplantation and were detectable for at least 12 months
(see Fig E1, A and B, in this article’s Online Repository at
www.jacionline.org). IgE was specific for donor MHC antigens
because IgE did not develop to unrelated MHC class I antigens
(see Fig E2 in this article’s Online Repository at
www.jacionline.org). In addition, I-Ed–specific IgE was
detectable 5 weeks after transplantation (Fig 1, C). Moreover,
C3H (H-2k) mice were used as alternative skin graft donors,
and BALB/c mice were used as an alternative recipient in
addition to C57BL/6 mice. Again, anti-MHC class I IgE
(ie, Kk- and Dk-specific IgE) developed on rejection, with
BALB/c recipients showing significantly greater levels ofMHC-specific IgE than C57BL/6 recipients (Fig 1, D and E).
I-Ek–specific IgE was detectable in neither BALB/c nor
C57BL/6 recipients (Fig 1, F).
In parallel, the more abundant IgG subclasses were analyzed.
Significantly increased levels of Kd- and Dd-specific IgG1, IgG2a/c,
IgG2b, and IgG3 were detected compared with pretransplantation
baseline levels on skin rejection in the BALB/c to C57BL/6
combination (see Fig E1, C-J). Thus both TH1- and TH2-
associated IgG subclasses were present in sera of recipient mice.32
Because IgE, in contrast to IgG, is not heat stable,33-36 serumwas
heat inactivated to rule out that the detection antibody potentially
cross-reacts with the more abundant MHC-specific IgG and to
confirm that the IgE signal detected in the ELISAwas specific for
IgE. Heat inactivation eliminated the H-2K/D–specific IgE signal,
whereas the H-2K/D–specific IgG signal remained unaltered (see
Fig E3 in this article’s Online Repository at www.jacionline.org),
demonstrating the specificity of the IgE signal.
Next, we evaluated donor-specific IgE in a primarily
vascularized heterotopic heart transplant model. The same
FIG 2. Rejection of fully mismatched skin grafts also induces a TH2 T-cell response. Splenocytes (Spleen) or
lymph node cells (Lymph nodes) of BALB/c mice that rejected C3H skin grafts were isolated 3 weeks after
transplantation. A-D, Cells were stimulated for 6 hours with phorbol 12-myristate 13-acetate and ionomycin
and analyzed by using flow cytometry by gating on CD31CD41 cells and intracellular staining for IL-4
(Fig 2, A and B, showing one representative picture of 6) and IFN-g (Fig 2, C and D, showing one
representative plot of 6). Additionally, BALB/c splenocytes from naive or C3H skin recipients (allograft)
were stimulated for 4 days with irradiated C3H (donor) or BALB/c (self) splenocytes. E-L, Subsequently,
supernatants were analyzed with the Luminex ProcartaPlex to determine the indicated cytokines (n 5 6
for allografts and n 5 4 for naive). P values were calculated with the Mann-Whitney U test. *P < .05.
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experiments were tested, with all heart grafts being rejected
within 11 days. Again, all recipient mice had detectable levels of
donor MHC class I–specific IgE (Fig 1, G, H, J, and K), which
were greater in BALB/c than in C57BL/6 mice. With regard to
MHC class II, again I-Ed– but not I-Ek–specific IgE was induced
(Fig 1, I and L). Taken together, these results show that IgE
specific for donor MHC class I and II antigens develops during
rejection of skin and heart allografts.Rejection of allogeneic skin grafts is associated
with a TH2 T-cell response
Because IgE induction is dependent on TH2 cytokines,
32 we
assessed whether skin graft rejection in the models used would
elicit a systemic TH2 response, as was shown in other
transplantation settings.31,37,38 A small but clearly distinguishable
CD41 cell population positive for IL-4 was detected (Fig 2, A andB) in addition to TH1-associated CD4
1IFN-g1 cells in spleens
and lymph nodes of BALB/c mice that had rejected C3H skin
(Fig 2, C and D). Further recipient splenocytes secreted IL-4,
IL-5, IL-6, IL-13, IFN-g, TNF-a, and IL-12p70 on cocultivation
with irradiated donor splenocytes (Fig 2, E-L). Hence a
donor-specific and most likely polyclonal systemic TH2 response
accompanies the development of donor-specific IgE.Functional activity of donor-specific IgE
IgE is the only isotype capable of efficiently binding through
FcεRI to basophils and mast cells and to trigger degranulation on
antigen-specific cross-linking. Therefore the functional activity
of MHC-specific IgE was assessed by incubating sera of BALB/c
mice that had rejected C3H skin with a basophil cell line that
expresses FcεRI. Subsequently, respective donor MHC antigens
(ie, recombinant monomers Kk or Dk, respectively) were added,
and degranulation was measured through a surrogate marker
FIG 3. Functional activity of donor-specific IgE developing after allogeneic murine allotransplantation.
A and B, IgE-containing serum from C3H skin-grafted BALB/c mice (n Serum, pre-transplantation; s Serum,
post-transplantation) loaded onto basophils leads to mediator release (b-hexosaminidase release as a
surrogate marker for histamine) on stimulation with recombinant donor (H-2Kk and H-2Dk) but not with
nonsensitized (H-2Kd and H-2Dd) MHC antigens (non. sens. Ag) or without antigen (w/o Ag) in vitro. Pooled
data of 3 independent experiments are shown. C-E, In vivo degranulation shown by injecting Evan blue
intravenously into naive or C3H skin-grafted BALB/c mice and subsequently challenging the mice
intradermally with recombinant donor MHC antigens (rH-2Kk and rH-2Dk), recombinant self MHC class I
antigens (rH-2Dd), and a mast cell degranulator (Pos. 48/80) or H-2Dd (ie, negative control). Mast cell
degranulation leads to vascular leakiness shown by means of blue intradermal staining. Fig 3, C, shows
a representative photo of one of 8 sensitized mice in 2 independent experiments. Fig 3, D, shows a
representative photo of one of 6 naive mice in 2 independent experiments. Fig 3, E, shows the percentage
of positive mice on H-2Kk and H-2Dk stimulation in sensitized and naive mice. P values were calculated with
the Mann-Whitney U (Fig 3, A and B) or x2 (Fig 3, E) tests. *P < .05 and ***P <_ .001, respectively.
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release, but unrelated nonsensitized MHC antigens did not
(Fig 3, A and B).
To assess whether the MHC-specific IgE was also functional
in vivo, we performed a cutaneous type I hypersensitivity reaction
assay whereby BALB/c mice were sensitized with C3H skin
grafts. Three to 5 weeks after transplantation, the mice received
an intravenous injection of Evans blue and were challenged
intradermally with recombinant Kk and Dk. After challenge
with donor MHC class I antigen, mast cell degranulation was
visible in most skin-grafted mice (Fig 3, C-E). Taken together,
MHC-specific IgE is functionally active in vitro and in vivo and
mediates mast cell/basophil degranulation on stimulation with
the specific sensitized MHC class I antigens.MHC-specific IgE is also induced in a murine model
of humoral heart allograft rejection
Although acute skin and heart graft rejection in untreated
recipients leads to a donor-specific humoral response, the
observed acute rejection-induced graft injury is largely cell
mediated.39 Recently, a heart transplant model eliciting a
predominantly humoral rejection associated with IgG DSAs
was developed by transplanting Bm12.Kd.IE donor hearts into
B6 recipients.40,41 In this setting donor hearts are not rejected
acutely, and chronic graft injury is associated with germinal
center development, anti-class I plus II alloantibody responses,
and graft vasculopathy. The Bm12.Kd.IE mouse differs fromthe C57BL/6 mouse by 1 MHC class I antigen (ie, Kd) and 2
MHC class II antigens (ie, I-Ed and I-Abm12).40
To test whether donor MHC-specific IgE also develops during
humoral graft rejection, we analyzed the sera of B6 recipients
undergoing transplantation with a Bm12.Kd.IE heart for
donor-specific (ie, Kd and I-Ed) IgG1 and IgE. Most recipients
had detectable levels of Kd– and I-Ed–specific IgE (and IgG1;
Fig 4, A, B, D, and E). No antibodies against the unrelated
(nondonor) Dd antigen were detected (Fig 4, C and F).
Histopathology of the explanted hearts was characterized by
high-grade intimal arteritis in larger-caliber vessels (ie, coronary
arteries), whereas small arteries and capillaries were not affected.
The edematous myocardium showed very little inflammation but
focal necrosis of the ischemic type, most likely resulting from
occlusive intimal arteritis (Fig 4, G). The transplanted hearts
were also stained immunohistochemically for C4d deposition.
All analyzed hearts demonstrated C4d1 staining of endothelial
cells, primarily in arterioles and capillaries, which is comparable
with the staining pattern in clinical ABMR (Fig 4, H). Thus
donor-specific IgE develops during chronic ABMR of a primarily
vascularized heart graft.HLA class I and II antigen–specific IgE is detectable
in sensitized kidney transplant patients
Next, we investigated whether MHC-specific IgE occurs in the
clinical setting. Therefore we analyzed sera of a pilot cohort of
sensitized kidney transplant recipients who had rejected a kidney
TABLE I. Number of positive HLA class I and II reactions for IgE and IgG
IgE HLA class I HLA class II IgG HLA class I HLA class II
Positive 5 MFI > mean
MFI of 3 healthy control
subjects 1 2*SD and
MFI > 25
No. of positive
reactions
No. of positive
reactions
Positive
MFI > 1000
No. of positive
reactions
No. of positive
reactions
Patient 1 34 14 Patient 1 89 68
Patient 2 16 22 Patient 2 52 36
Patient 3 0 7 Patient 3 2 24
Patient 4 37 21 Patient 4 53 35
Patient 5 45 21 Patient 5 67 50
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FIG 4. MHC-specific IgE is induced in a murine model of humoral heart allograft rejection. A-F, Analysis of
IgE (Fig 4,A-C) or IgG1 (Fig 4,D-F) specific for MHC class I (ie, H-2K
d5 donor and H-2Dd5 nondonor) or MHC
class II (ie, I-Ed5 donor) antigens in sera of C57BL/6 recipients grafted with Bm12.Kd.IE hearts at weeks (w) 3
or 5 after transplantation (n 5 4). P values were calculated with the Mann-Whitney U test. *P < .05. G,
Representative hematoxylin and eosin staining showing high-grade intimal arteritis (arrow and insert) in
larger-caliber vessels (coronary arteries). Small arteries and capillaries are not affected. The edematous
myocardium shows very little inflammation but does show focal necrosis of the ischemic type (triangles),
most likely resulting from occlusive intimal arteritis. H, Representative C4d staining (brown chromogen)
showing the typical staining pattern for ABMR (ie, endothelial C4d deposition in arterioles and capillaries).
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6 FARKAS ET ALgraft. All 5 patients were broadly sensitized against HLA class I
(see Fig E4 in this article’s Online Repository at www.jacionline.
org) and/or HLA class II (see Fig E5 in this article’s Online
Repository at www.jacionline.org) antigens, as assessed by using
a standard HLA-specific IgG single-antigen bead (SAB) assay
(Table I).
The same patient samples were then analyzed for HLA-specific
IgE by using a modified SAB assay with a non–cross-reactinganti-IgE–detecting antibody (clone MHE-18). Because of the
drastically lower physiologic levels of IgE compared with IgG,
the expected fluorescence intensity was much lower, and the
threshold for positive bead reactivity was adjusted accordingly in
that the mean median fluorescence intensity (MFI) of 3 healthy
control subjects plus 2*SDs was defined as a threshold for each
antigen (with an MFI > 25 as the lower limit). In 4 of 5 tested
patients, HLA class I–specific IgE was detected (Fig 5). Among
FIG 5. Anti–HLA class I IgE in kidney transplant recipients. A-E, HLA-specific IgE levels were measured in
sera of kidney transplant recipients with high levels of IgG DSAs with One Lambda LABScreen Single
Antigen HLA Class I kits. IgE binding to several HLA class I antigens was detectable in 4 of 5 analyzed
patients. Each panel shows the MFI representing a single patient compared with the mean of 3 healthy
control subjects (HC) plus 2*SDs. Red arrows indicate kidney donor-specific bead reactivity. For patients
with HLA-specific IgE, only positive beads are shown.
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FARKAS ET AL 7the positive IgE reactivities, several were specific for donor HLA
antigens (indicated with red arrows in Fig 5). Furthermore, HLA
class II–specific IgE was also detectable in the sera of all 5
patients (see Fig E6, A-E, in this article’s Online Repository at
www.jacionline.org).
Serum was heat inactivated to denature IgE antibodies
(analogous to the murine studies described above) to assess the
specificity of the assay for IgE. IgG in heat-inactivated serum is
known to be stable.42 IgE signals were decreased for both HLA
class I and HLA class II, supporting a high specificity for IgE
in the assay (data not shown). No cross-reactivity with other
isotypes and high specificity of the anti-human IgE antibody
(MHE-18) for IgE was confirmed by using ELISA MHE-18
binding to a panel of coated human isotypes, as previously
described (see Fig E6, F).43 The number of donor-specific HLA
reactivities (IgG and IgE) for each tested patient is summarized
in Table I. These results demonstrate that IgE antibodies specific
for HLA class I and class II antigens are detectable in sensitized
kidney transplant patients.
In western countries type I allergy is prevalent in
approximately 25% of subjects and is thus the main disorder
associated with increased serum IgE levels. Therefore we tested
sera of patients undergoing transplantation for the presence of
allergen-specific IgE by using a comprehensive multiallergen test
containing the most common allergens.44 Only 1 patient (patient
5) had detectable levels of allergen-specific IgE in the allergenarray chip, with reactivities against Ara h 1 (ie, major
peanut allergen), Der p 4 (ie, house dust mite allergen), Phl p 1,
Phl p 4, and Phl p 5b (ie, 3 major grass pollen allergens of Phleum
pratense; see Fig E7, A and B, in this article’s Online Repository
at www.jacionline.org). Hence 4 of 5 patients had positive results
for HLA-specific IgE without being atopic and without having
allergen-specific IgE.
To address the reverse question of whether IgE that develops
during the course of type I allergy cross-reacts with HLA
antigens, we tested whether sera of allergic patients known to
have very high levels of total IgE contain HLA-specific IgE. No
HLA class I– or HLA class II–specific IgE was detectable in a
group of allergic patients, indicating that HLA-specific
IgE develops de novo after transplantation because of
antigen-specific sensitization (see Fig E7, C-H).
A previous publication has shown frequent development of
HLA-specific IgG during pregnancy.45 To address the question of
whether anti-HLA IgE can develop as a consequence of
sensitizing events other than transplant rejection, we analyzed
sera from 10 pregnant women known to have high levels of
HLA-specific IgG. Eight of 10 women had detectable
anti–HLA class I IgE antibodies, and 7 of 10 had anti–HLA class
II antibodies (Fig 6, A-C).
Collectively, these results demonstrate that IgE specific for
donor HLA class I and II antigens occurs in selected kidney
transplant patients as part of the antigen-specific alloresponse.
FIG 6. HLA-specific IgE also occurs during pregnancy, and donor HLA-specific IgE found in sera of kidney
transplant patients shows functional activity. A-C, HLA-specific IgE levels were measured in sera of
pregnant women known to have positive HLA IgG results. Results obtained with One Lambda LABScreen
Single Antigen HLA Class I (Fig 6, A) and Class II (Fig 6, B) kits are shown. Each panel (Fig 6, A and B) shows
the MFI of a representative woman compared with the mean of 3 healthy control subjects (HC) plus 2*SDs.
Only the positive reactivities are shown. In Fig 6, C, reactivities of the 10 analyzed women are summarized.
D, IgE-containing sera from kidney transplant patients were used to load a rat basophil cell line transfected
to express human FcεRI. We tested patients that were either IgE positive (ie, Pat. pos. 5 patients 2 and 4) or
IgE negative (ie, Pat. neg. 5 patients 1 and 3) for the respective HLA antigen (ie, DQA1). Cells were then
stimulated with or without (w/o) beads bearing the respective HLA antigen (Ag). Mediator release
(ie, b-hexosaminidase) wasmeasured and compared with healthy volunteer control sera (HC), sera and cells
without antigen beads, or only beads and cells without serum.
J ALLERGY CLIN IMMUNOL
nnn 2018
8 FARKAS ET ALHLA-specific IgE from renal transplant recipients is
functional in vitro and triggers basophil
degranulation
In a next step the functionality of HLA-specific IgE was
assessed. Basophils transfected to express human FcεRI were
incubated with patient sera and stimulated with selected beads
expressing single HLA antigens (namely A3, A24, A32, andDQA1). Basophil degranulation occurred on stimulation with
specific class I (see Fig E8 in this article’s Online Repository at
www.jacionline.org) or class II (Fig 6, D) antigens, to which the
patient had a positive IgE signal but not on stimulation with anti-
gen, to which no positive IgE signal was detectable. Furthermore,
heat inactivation of serum abrogated basophil degranulation (see
Fig E9 in this article’s Online Repository at www.jacionline.org).
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functional in mediating basophil degranulation.Human kidney tissue contains FcεRI1 cells
The major functionality of IgE depends on tissue-resident cells
expressing the IgE high-affinity receptor FcεRI. To determine
whether anti-HLA IgE developing during transplant rejection has
a target in the kidney, we analyzed tissue homogenates generated
from human kidneys obtained from organ donors for
FcεRI-expressing cell subsets. CD451FcεRI1 cells were
detectable in the medulla and cortex, including basophils
(CD451CD1231c-Kit1FcεRI1) and mast cells (CD451
c-Kit1FcεRI1), which were present in 7 of 7 kidney tissue
samples derived from different donors (see Fig E10 in this
article’s Online Repository at www.jacionline.org). These data
demonstrate that the human kidney contains FcεRI-expressing
cell populations that present a local intragraft target for
anti-HLA IgE that develop during kidney transplant rejection.DISCUSSION
This study demonstrates that functional IgE specific for donor
MHC class I and class II antigens develops in murine and human
recipients of solid allografts undergoing rejection. To our
knowledge, this is the first report that DSAs of the IgE isotype
develop during graft rejection.
Donor-specific IgE developed in 4 different mouse strain
combinations using distinct MHC haplotypes and on rejection
of 2 different types of grafts (ie, heart and skin). IgE DSAs were
rapidly induced on acute rejection and persisted long-term (up to
12 months). Notably, MHC-specific IgE developed during
humoral heart graft rejection, as characterized by the
vasculopathy reminiscent of clinical ABMR. The functional
capacity ofMHC-specific IgE is indicated by induction of effector
cell degranulation in vitro and in vivo on antigen stimulation.
Importantly, preclinical mouse data were corroborated in
sensitized patients experiencing kidney graft rejection, in which
IgE specific for donor HLA class I and II antigens wasmeasurable
in serum. The other HLA specificities (ie, nondonor HLA
antigens), which are also commonly observed for IgG,46 might
be due to epitope sharing, which was already shown for several
HLA antigens.47-49 Alternatively, they might be due to previous
sensitization events, such as pregnancies, blood transfusions, or
previous transplantations. Indeed, our data show that anti-HLA
IgE can also develop during pregnancy. As in murine models,
MHC-specific IgE was functional in inducing basophil
degranulation on antigen stimulation. Most of the kidney
transplant patients with anti-HLA IgE did not have detectable
IgE to an array containing most of clinically relevant allergens.44
Likewise, selected allergic patients with very high levels of total
IgE had no detectable levels of HLA-specific IgEwithin the broad
range of HLAmolecules tested. This supports the assumption that
induction of HLA-specific IgE is due to antigen-specific humoral
sensitization occurring during alloreactivity.
The observed MFIs for anti-HLA IgE were low, which was
expected, given the fact that IgE is the least abundant isotype in
serum and might be bound to donor HLA antigens in the graft.
Therefore an MFI cutoff sui generis had to be defined and was
used for determining IgE positivity. The validity of the signal
was tested in a series of control experiments, including heatinactivation and selection of an anti-IgE–detecting antibody that
does not bind other antibody isotypes. Notably, positivity for
HLA-specific IgE in the Luminex assay correlated with mediator
release, providing strong evidence for the validity of the HLA IgE
Luminex assay.
For alloantibody generation, B cells are required to present
HLA antigens to T cells through the indirect pathway of
allorecognition.50 In turn, interaction of B cells with CD41T cells
leads to secretion of cytokines and generation of class-switched
alloantibodies.51-53 IgE induction is dependent on IL-4 and other
TH2-associated cytokines,
32 which were evident in the murine
setting of graft rejection. A TH2-skewed alloresponse was
associated with graft acceptance in some studies, but
accumulating evidence suggests that prolonged exposure to
TH2-associated cytokines promotes graft rejection.
37,54 Previous
preclinical reports described TH2-associated graft rejection linked
to eosinophilic andmast cell infiltrates,29,55,56 and eosinophils and
mast cells were also noted in the process of graft rejection in
patients undergoing heart, lung, kidney, and liver transplanta-
tion.57-59 The present study reveals that MHC-specific IgE occurs
during allograft rejection, thereby providing a possible humoral
effector mechanism of TH2-associated alloimmunity.
Recent studies in patients with autoimmune diseases have
revealed a novel link between IgE and tissue damage.
Self-reactive IgE was capable of enhancing the inflammatory
response by IgG and thereby directly contributing to tissue
damage in a murine systemic lupus erythematosus model.27
Here we demonstrate the presence of FcεRI-expressing cells in
the medulla and cortex of human kidneys, providing the target
cells necessary for local IgE-mediated effector functions. Thus
anti-donor IgE developing after transplantation might bind to
tissue-resident mast cells/basophils in the allograft. Cell-bound
IgE can then be cross-linked by either soluble donor HLA antigen,
likely in form of HLA-containing exosomes,60,61 or by HLA
expressed on donor parenchymal or hematopoietic cells,
triggering degranulation and mediator release. The ensuing
proinflammatory response could directly inflict local damage
and reinforce the anti-donor T-cell response through various
mediators, including TNF-a and IL-6.62,63
We gratefully acknowledge the National Institutes of Health’s Tetramer
Core Facility for provision of MHC class I H-2Kk, MHC class I H-2Dk, MHC
class I H-2Kd, MHC class I H-2Dd, MHC class II I-Ek, and MHC class II I-Ed
monomers.
Key messages
d Anti-donor MHC IgE develops in several mouse models
of heart and skin transplantation, including a model of
antibody-mediated heart graft rejection.
d Anti-donor HLA IgE is detected in a cohort of sensitized
kidney transplant recipients.
d Functionality of both mouse and human anti-MHC/HLA
IgE is shown in in vitro and in vivo mediator release
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Animals
Female C57BL/6 (H-2b), BALB/c (H-2d), and C3H/HeNCrl (H-2k) mice
were purchased from Charles River Laboratories (Sulzfeld, Germany).
Bm12.Kd.IEE1micewere generated and bred in the laboratory of G. Pettigrew.
Mice were housed under specific pathogen-free conditions in individually
ventilated filter cages (up to 5 mice) on sterile standard bedding; sterile water
and a standard pellet diet were administered ad libitum. Housing rooms were
equipped with a 12-hour light cycle. Mice were used at 6 to 8 weeks of age,
with an average weight of 18 to 22 g.
Skin transplantation
Full-thickness tail skin from fully mismatched BALB/c (H-2d) and C3H
(H-2k) mice was grafted and visually inspected thereafter at short intervals.
Grafts were considered to be rejected, when less than 10% remained viable.
Cardiac transplantation
Cervical heterotopic heart transplantation was performed with a modified
cuff technique for revascularization, as described previously.E2 Briefly, after
preparation of the right external jugular vein and common carotid artery cuffs,
the donor heart was harvested and transferred to the recipient’s neck. Themain
pulmonary artery and aorta were anastomosed to the recipient’s external
jugular vein and carotid artery, respectively. Cardiac graft survival was
determined by means of daily palpation and observation under the
microscope, with complete cessation of heart beats indicating the end of graft
survival. Bm12.Kd.IE hearts were transplanted intra-abdominally, as
described by Ali Jason et al.E3
Recombinant H-2K, H-2D, and I-E monomers
MHC class I H-2Kk, MHC class I H-2Dk, MHC class I H-2Kd, MHC class I
H-2Dd, MHC class II I-Ek, and MHC class II I-Ed monomers were kindly
provided by the National Institutes of Health’s Tetramer Core Facility.
H-2K–, H-2D–, and I-E–specific ELISA
To measure MHC-specific antibodies in the sera of transplanted mice, we
modified an ELISA protocol originally developed to measure allergen-specific
IgE levels in serum.E4 Plates were coated with rH-2Kk, rH-2Kd, rH-2Dk, rH-2Dd,
I-Ed, or I-Ek (5 mg/mL), for I-Ek anti-I-A/I-E mAb clone M5/114.15.2,
BioLegend, San Diego, Calif 1:1000, served as a positive control. Sera were
diluted 1:2.5 for IgE and 1:125 for IgG1, IgG2a/b, and IgG3, respectively. Where
indicated, sera were heat inactivated at 568C for 60 minutes. Bound antibodies
were detected with rat anti-mouse IgE (clone R35-72), IgG1 (clone A85-1),
IgG2a/c (clone R19-15), IgG2b (clone R9-91), or IgG3 (clone R2-38)
mAbs (BD, San Diego, Calif) diluted 1:1000, and a horseradish peroxidase
(HRP)–coupled goat anti-rat antiserum (Amersham Biosciences, Little Chalfont,
United Kingdom) was diluted 1:2000. The substrate for HRP was ABTS
(60 mmol/L citric acid, 77 mmol/L Na2HPO4 3 2 H2O, 1.7 mmol/L ABTS
[Sigma, St Louis, Mo], and 3 mmol/L H2O2). Absorption was measured with a
Victor microplate reader (PerkinElmer, Waltham, Mass).
Intracellular cytokine staining
One million splenocytes or lymph node cells were incubated for 5 hours
with phorbol 12-myristate 13-acetate/ionomycin (at 50 ng/mL and 1 mg/mL,
respectively) in the presence of BD GolgiStop Protein Transport Inhibitor.
Subsequently, cells were stained according to the protocol of the mouse
TH1/TH2/TH17 Phenotyping Kit (BD Bioscience, Franklin Lakes, NJ), with
additional phycoerythrin (PE)-Cy7–conjugated anti-CD3 staining (clone
17A2; BioLegend, SanDiego, Calif). Flow cytometric analysis was performed
with the BD FACSCanto II and FlowJo software (TreeStar, Ashland, Ore).
Detection of secreted cytokines in MLR
supernatants
Aliquots of 4 3 105 responder cells were incubated in triplicates with
4 3 105 irradiated (30 Gy) stimulator cells (either allogeneic or syngeneicas a control) fromBALB/c, C3H, and C57BL/6mice for 4 days. Subsequently,
supernatants were analyzed with the ProcartaPlex Mouse Essential Th1/Th2
Cytokine Panel (6-plex; eBioscience, San Diego, Calif), according to the
manufacturer’s protocol. Samples were measured with a MAGPIX instrument
(Luminex, Austin, Tex) and xPONENT software (Luminex).
Rat basophil leukemia cell degranulation assay
The rat basophil leukemia (RBL)22H3 cell subline was cultured, as
described previously,E5 in RPMI 1640 medium (Biochrom, Berlin, Germany)
containing 10% FCS. Cells (4 3 104) were plated in 96-well tissue-culture
plates (Greiner Bio-One, Kremsm€unster, Austria), loaded with 1:1.5 diluted
mouse sera, and incubated for 2 hours at 378C in a 5% CO2 atmosphere.
Supernatants were removed, and the cell layer was washed with 23 Tyrode
buffer (137 mmol/L NaCl, 2.7 mmol/L KCl, 0.5 mmol/L MgCl2, 1.8 mmol/
L CaCl2, 0.4 mmol/L NaH2PO4, 5.6 mmol/L D-glucose, 12 mmol/L NaHCO3,
10 mmol/L HEPES, and 0.1% [wt/vol] BSA [pH 7.2]). Preloaded cells were
stimulated with rH-2Kk, rH-2Kd, rH-2Dk, or rH-2Dd (0.03 mg/well) for
30 minutes at 378C. Supernatants were analyzed for b-hexosaminidase
activity by means of incubation with the substrate 80 mmol/L
4-methylumbelliferyl-N-acetyl-b-D-glucosamide (Sigma-Aldrich) in citrate
buffer (0.1 mol/L, pH 4.5) for 1 hour at 378C. The reaction was stopped by
addition of 100 mL of glycine buffer (0.2 mol/L glycine and 0.2 mol/L
NaCl, pH 10.7), and fluorescence was measured at an excitation/emission of
360/465 nm by using a fluorescence microplate reader (PerkinElmer). Results
are reported as a percentage of total b-hexosaminidase released after addition
of 1% Triton X-100. Determinations were done in triplicates.
Mediator release assay with humanized RBL cells
transfected with human FcεRI
RBL-2H3 cells transfectedE6,E7 with cDNA coding for the human
high-affinity IgE receptor chains a, b, and g were maintained in RPMI
1640 medium supplemented with 5% FBS, 4 mmol/L l-glutamine and
1 mg/mL gentamicin sulfate.E6 Cells were incubated with sera from patients
or healthy control subjects and incubated with selected single HLA
antigens coupled to single-antigen beads (One Lambda, Canoga Park, Calif).
b-Hexosaminidase release from activated RBL cells was measured,
as previously described.E8
Cutaneous type I hypersensitivity reaction
An adapted protocol previously described byWiedermann et alE7 was used.
Briefly, mice were injected intravenously with 100 mL of 0.5% Evans blue
(Sigma-Aldrich). Subsequently, 30 mL of rH2-Kk and rH-2Dk (2 mg/mL
diluted in PBS) was injected intradermally into the shaved abdominal skin,
as described previously. As a positive control, the mast cell–degranulating
compound 48/80 (20 mg/mL; Sigma-Aldrich) was injected intradermally,
whereas PBS or rH-2Dd (2 mg/mL diluted in PBS) was injected as a negative
control. Fifteen minutes after injection, mice were killed, and the blue color
intensity of a positive skin reaction caused by vascular permeability
was compared with the individual positive and negative control on inverted
skin.
Histologic analysis
Four-micrometer sections of heart tissueswere cut from paraffin-embedded
tissue fixed in 4.5% formalin (with a buffered pH of 7.5), stained with
hematoxylin and eosin according to standard protocols, analyzed, and graded
by an experienced pathologist. For C4d, antigen retrieval was done with
Pascal/Tris EDTA, pH 9, and subsequent blocking in 3%H2O2/PBS, followed
by avidin-biotin block (Vector Laboratories, Burlingame, Calif) and 10% goat
serum (Sigma-Aldrich). Polyclonal rabbit anti-mouse C4d (Hycult Biotech,
Uden, The Netherlands) was diluted 1:50 in PBS and incubated overnight at
48C PBS, and biotinylated polyclonal goat anti-rabbit serum (Vector
Laboratories) was diluted 1:300 in PBS and incubated at room temperature
for 30 minutes. AEC-Chromogen (3-amino-9-ethylcarbazole) was added for
10 minutes prior to hematoxylin counterstaining performed for 1 minute,
before embedding the samples.
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Sera were obtained from patients undergoing kidney transplantation who
were known to be broadly sensitized to high levels of HLA-specific antibodies
and were waiting for retransplantation at the Vienna Transplantation Unit. All
patients experienced at least 1 episode of histopathologically proven rejection
(in 4 of 5 there were clear signs of an antibody-mediated or mixed rejection
type). Samples were placed in aliquots and frozen at 2808C.
Assessing isotype specificity of anti-human IgE by
using ELISA
As described by Lupinek et al,E9 ELISA plates (Costar; Corning, Corning,
NY) were coated (coating buffer, 0.1 mol/L NaHCO3 [pH 9.6]) overnight at
48C with 300 ng of human IgM, IgG1, IgG2, IgG3, and IgG4 (Sigma-Aldrich)
and IgE purified from serum of an allergic patient by using affinity
chromatography.E10 After washing with PBST (PBS [pH 7.5] with 0.05%
[vol/vol] Tween 20) and blocking with PBST/1% (wt/vol) BSA for 2.5 hours at
378C, 0.2 mg/mL biotin-conjugated anti-human IgE mAb (clone MHE-18;
BioLegend) diluted in PBST/0.5% (wt/vol) BSA was applied and incubated
overnight at 48C. After washing with PBST (PBS and 0.5% [vol/vol] Tween
20), Streptavidin-HRP conjugates (BD Biosciences) diluted 1:10,000 in PBST/
0.5% (wt/vol) BSAwere applied, and after incubation at room temperature for
30 minutes, unbound detection antibody was removed by washing with PBST.
The substrate for HRP was ABTS (60 mmol/L citric acid, 77 mmol/L
Na2HPO4 3 2H2O, 1.7 mmol/L ABTS [Sigma], and 3 mmol/L H2O2). All
samples were measured in triplicates, and results show mean values with SDs.
Detection of HLA-specific IgE
Deposition of IgE to single-antigen beads (SABs) were assessed by using a
modified protocol for IgG detection by using One Lambda SAB kits (LABScreen
Single Antigen HLA class I and HLA class II AntibodyDetection Tests). In brief,
1 mL of SABs was first incubated with 4 mL of patient sera, and beads were then
washed and incubated with biotin-conjugated anti-human IgE mAb (dilution
1:20, clone MHE-18; BioLegend). In a second step PE-conjugated streptavidin
(dilution 1:200; eBioscience, San Diego, Calif) was added. Samples were
measured on a Luminex flow analyzer. The presence of HLA-specific IgE was
determined based on baseline SAB reactivity patterns of 3 healthy volunteers.
SAB reactivities with an MFI greater than the corresponding mean MFI of 3
healthy volunteers plus 2*SDs were considered positive. We decided to have a
minimumMFI of 25 because of the observation that in the basophil release assay
the lowest MFI for an HLA-specific IgE antibody that triggered a release was 40,
whereas another bead value with an MFI of 21.5 did not. Additionally, because
some mean MFIs of the healthy control subjects exceeded 30, we concluded that
some beads have a stronger background signal. Therefore each bead value also
had to be greater than the mean of the 3 healthy control subjects plus 2*SDs to
make our assay more stringent. As a control, in selected samples IgE reactivities
were destroyed by means of heat inactivation before bead incubation.
Detection of allergen-specific IgE in patient sera
Patient sera were analyzed with the MeDALL allergen chip for
allergen-specific IgE, as described by Lupinek et al.E11
Detection of total IgE in patient sera
Patient sera were analyzed with ImmunoCAP total IgE kits (Thermo Fisher
Scientific, Waltham, Mass), according to the manufacturer’s manual.
Cell isolation from human renal tissue
Human tissue (30 g) was obtained from organ donors in whom consent for
research was present. Kidney tissue was minced, incubated in digest mix for
30 minutes at 378C, dissociated with a gentleMACS machine (Miltenyi
Biotech, Bisley, United Kingdom) and then passed sequentially through 100-,
50-, and 30-mm cell strainers. Addition of 44% Percoll followed by
centrifugation was used to remove debris. Cells were blocked with human
FcR block (Miltenyi Biotech) and incubated with antibodies for 1 hour at 48C,
followed by Live/Dead cell staining (Zombie Aqua Fixable Viability Kit;
BioLegend) for 20 minutes at room temperature. Cell-surface receptorstaining was undertaken at room temperature. Samples were processed on a
Fortessa flow cytometer (Becton Dickinson, Basel, Switzerland), and data
were analyzed with FlowJo software (TreeStar). Antibodies were used at
1:200 as follows: mouse anti-human CD45 (PE; clone 2D1; eBioscience),
mouse anti-human CD3 (A700, clone UCHT1; eBioscience), mouse
anti-human CD15 (A700, clone U63D; BioLegend), mouse anti-human
CD19 (A700, clone HIB19; eBioscience), mouse anti-human MHC class II
(BV785, clone L243; eBioscience), mouse anti-human CD123 (fluorescein
isothiocyanate; clone 6H6; eBioscience), mouse anti-human c-Kit
(allophycocyanin; clone YB5B8; eBioscience), and mouse anti-human IgεR
(peridinin-chlorophyll-protein complex; clone AER-37; BioLegend).
Study approval
All human samples were collected on written informed consent. The studies
were approved by the ethics review board of the Medical University of Vienna
(EK no. 267/2011). Ethical approval for the kidney tissues was granted by the
local ethics committee of the University of Cambridge (REC12/EE/0446 and
REC15/EE/0152), and the studies were also approved by NHS Blood and
Transplant. We received sera from pregnant women with high HLA IgG levels
from the Biobank for Pregnancies at the Department of Obstetrics and
Feto-maternal Medicine, Medical University of Vienna, Vienna General
Hospital (‘‘Biobank’’; EK nos. 619/2006 and 559/2015, respectively). All
murine experiments were approved by the Ethics and Animal Welfare Com-
mittee of the Medical University of Vienna and were performed in accordance
with national and international guidelines of laboratory animal care. All animals
received humane care in compliance with FELASA and ARRIVE and were
approved by the Austrian Federal Ministry of Science, Research and Economy
BMWF GZ: 66.009/0295-1I/3b/2011 and GZ 66.009/0230- II/3b/2011.
Statistical analysis
The reported P values are results of 2-sided Mann–Whitney U or x2 tests.
P values of less than .05 were considered statistically significant. Whiskers in
box plots indicate the minimum to maximum range of the values, and error
bars indicate SDs.
FIG E1. MHC-specific IgG subtypes and IgE persistence after skin transplantation. Antibody isotypes
(indicated in the respective y-axis legend) specific for MHC class I (ie, H-2Kd [A, C, E, G, and I] and H-2Dd
[B, D, F, H, and J]) in the setting of BALB/c to C57BL/6J skin transplants. Antibody levels were measured
in sera of recipient mice at indicated time points (n 5 6). pre, Pre-transplantation; w, weeks after
transplantation. P values were calculated with the Mann-Whitney U test. *P < .05.
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FIG E2. Developing IgE is specific for donor MHC antigens. IgE specific for
MHC class I H-2Kd (A) and H-2Dd (B) antigens in the setting of the indicated
skin transplant combinations (ie, donor antigens for BALB/c to B6 and
nondonor antigens for C3H to B6 and C3H to BALB/c combinations).
Antibody levels were measured in sera of recipient mice (n 5 5 per group)
at indicated time points. pre, Pre-transplantation; w, weeks after
transplantation. P values were calculated with the Mann-Whitney U test.
*P < .05.
J ALLERGY CLIN IMMUNOL
VOLUME nnn, NUMBER nn
FARKAS ET AL 11.e4
FIG E3. Heat inactivation abrogates the MHC-specific IgE signal but not the signal for IgG1. IgE (A and B) or
IgG1 (C andD) specific for MHC class I (H-2K
k [Fig E3,A and C] and H-2Dk [Fig E3, B andD]) in naivemice or in
the setting of BALB/c to C57BL/6 skin transplants. Antibody levels were measured in pooled serum of
recipient mice with (HI) or without heat inactivation, as indicated. P values were calculated with the
Mann-Whitney U test. ***P <_ .001. ns, Not significant.
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FIG E4. Anti2HLA class I IgG levels measured with One Lambda LABScreen Single Antigen HLA Class II kits
in patients used for HLA-specific IgE analysis. A-E, Each panel shows the MFI for the panel of SABs.
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FIG E5. Anti2HLA class II IgG levelsmeasured with One Lambda LABScreen Single Antigen HLA Class II kits
in the patients used for HLA-specific IgE analysis. A-E, Each panel shows the MFI for the panel of SABs.
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FIG E6. Anti2HLA class II IgE in kidney transplant recipients (A-E). Antigen-specific IgE levels were
measured in sera of kidney transplant recipients with high levels of IgG DSAs waiting for retransplantation
with One Lambda LABScreen Single Antigen HLA Class II kits. IgE binding to several HLA class II antigens
was detectable in 5 of 5 analyzed patients. A-E,MFIs representing a single patient were compared with the
mean of 3 healthy control subjects (HC) plus 2*SDs. Red arrows indicate kidney donor2specific bead
reactivity. Only positive beads are shown. F, Anti-IgE clone MHE-18 was used to detect different human
(hu) antibody isotypes by using ELISA. Each column represents the mean OD of triplicates 6 SDs.
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FIG E7. HLA-specific IgE is not linked to atopy. A and B, Allergen-specific IgE levels were measured in sera
of kidney transplant recipients with detectable levels of HLA-specific IgE and 3 healthy control subjects.
Allergen-specific IgE levels against 176 relevant allergens (x-axis) were measured by using the MeDALL
array. IgE levels (y-axis) are displayed in ISAC standardized units, as described by Lupinek et al.E11 C-H,
HLA class I2specific (Fig E7, C-E) and HLA class II2specific (Fig E7, F-H) IgE levels were measured in sera
of 3 allergic patients with high levels of total IgE (assessed by using ImmunoCAP) with One Lambda
LABScreen Single Antigen HLA Class I or II kits. The MFI of each HLA bead was compared with the mean
of 3 healthy control subjects (HC) plus 2*SDs.
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FIG E8. Functional activity of donor HLA-specific IgE in sera of kidney transplant patients. IgE-containing
sera from kidney transplant patients were used to load a rat basophil cell line transfected to express human
FcεRI. We tested patients who were either IgE positive (Pat. pos.) or IgE negative (Pat. neg.) for the
respective HLA antigen. Cells were then stimulated with beads bearing a single HLA antigen
(A: A3-positive patients 1 and 4 and A3-negative patients 3 and 5; B: A24-positive patient 1 and A24-negative
patients 3-5; C: A32-positive patients 4 and 5 and A32-negative patients 2 and 3). Mediator release
(ie, b-hexosaminidase) wasmeasured and compared with healthy volunteer control sera (HC), sera and cells
without (w/o) antigen beads, or only beads and cells without sera.
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FIG E9. Heat inactivation abrogates MHC-specific basophil degranulation.
IgE-containing sera from kidney transplant patients were used to load a rat
basophil cell line transfected to express human FcεRI. Cells were then
stimulated with SABs bearing 1 donor-specific HLA-antigen (A32) and
mediator release (ie, b-hexosaminidase) was measured. Where indicated,
sera were heat inactivated (HI) to denature IgE.
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FIG E10. Human kidneys contain FcεRI1 cells. A, Representative fluorescence-activated cell-sorting
plots obtained from single-cell suspensions of human kidney cells demonstrating live CD451 cells that
are IgER1 (ie, FcεRI1; upper row). Live CD451CD1231cKit1 cells were identified, the majority of which
were IgER1 (middle and lower rows). B-D, Quantification of the proportion of IgER1 cells (Fig E10, B),
CD1231c-Kit1IgER1 basophils (Fig E10, C), and CD1232c-Kit1IgER1 mast cells (Fig E10, D) within the
CD451 gate in human cortex and medulla kidney samples. Each data point represents a kidney sample
from 1 subject.
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